Search Results - "Olier, C"

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer by Blancas, I., Olier, C., Conde, V., Bayo, J. L., Herrero, C., Zarcos-Pedrinaci, I., Carabantes, F., Baena-Cañada, J. M., Cruz, J., Ruiz-Borrego, M.

“…Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of…”
Get full text

Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease by Jara Sánchez, C., Olier Gárate, C., García-Donas Jiménez, J., Peñalver Párraga, J.

Get full text

Use of bevacizumab as a first-line treatment for metastatic breast cancer by Manso, L, Moreno, F, Márquez, R, Castelo, B, Arcediano, A, Arroyo, M, Ballesteros, A I, Calvo, I, Echarri, M J, Enrech, S, Gómez, A, González Del Val, R, López-Miranda, E, Martín-Angulo, M, Martínez-Jañez, N, Olier, C, Zamora, P

“…During clinical practice, it can be challenging, given the lack of response biomarkers, to identify the patients with metastatic breast cancer (mbca) who would…”
Get full text

Structural evolution of co-deposited Zn–Cr coatings produced by vacuum evaporation by Scott, C., Olier, C., Lamandé, A., Choquet, P., Chaleix, D.

“…Zn and Cr were evaporated simultaneously using two e-beam guns to heat crucibles containing the pure metals. The metallic vapors generated are intermixed and…”
Get full text

Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients by Mielgo Rubio, X., Sereno Moyano, M., Chara, L.E., López-Castro, R., Rubio-Martínez, J., Velastegui, A., Olier-Garate, C., Falagán, S., Gómez-Barreda, I., Riquelme, A., Silva-Ruiz, J., Moreno-Rubio, J., López, C., Bueno, C., Cardeña, A., Pérez-Fernández, E., Martí-Castelló, M.P., Sotelo-Lezama, M.J.

Get full text

2019P Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential by García, M. Esteban, Aguilar, E. Jimenez, González López, A.M., Bermejo, T. Robles, Sánchez, Y. Pernas, Peña, R. Avilés, Fernandez, E. Perez, Antona, S. Adeva, Cámara Vicario, J.C., Gárate, C. Olier, Polo, S. Hernando, Nuño, A. Hurtado, Muñoz, D. Moreno, Rubio, X. Mielgo

Get full text

398PDExtending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial by Salgado, M A V, Sepulveda Sanchez, J M, del barco, S, Pineda, E, Fuster, J, Navarro Martin, M, Herrero Ibañez, A, Alonso, M, Perez, J, Mesia, C, Munoz-Langa, J, de las Penas Bataller, R, Peralta, S, Olier, C, Pérez-Segura, P, Estival, A, Carrato, C, Saez, C, Gil, M J, Balana, C

“…Abstract Background Standard treatment of glioblastoma (GBM) is focal radiation with concomitant and adjuvant temozolomide (TMZ) for 6 cycles. The GEINO-14-01…”
Get full text

398PD - Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial by Salgado, M.A.V., Sepulveda Sanchez, J.M., del barco, S., Pineda, E., Fuster, J., Navarro Martin, M., Herrero Ibañez, A., Alonso, M., Perez, J., Mesia, C., Munoz-Langa, J., de las Penas Bataller, R., Peralta, S., Olier, C., Pérez-Segura, P., Estival, A., Carrato, C., Saez, C., Gil, M.J., Balana, C.

“…Standard treatment of glioblastoma (GBM) is focal radiation with concomitant and adjuvant temozolomide (TMZ) for 6 cycles. The GEINO-14-01 trial (NCT02209948)…”
Get full text

Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial by Salgado, M.A.V., Sepulveda Sanchez, J.M., del barco, S., Pineda, E., Fuster, J., Navarro Martin, M., Herrero Ibañez, A., Alonso, M., Perez, J., Mesia, C., Munoz-Langa, J., de las Penas Bataller, R., Peralta, S., Olier, C., Pérez-Segura, P., Estival, A., Carrato, C., Saez, C., Gil, M.J., Balana, C.

Get full text

P14.58 Extending adjuvant temozolomide longer than six cycles doesn’t add any benefit to glioblastoma patients according to the randomized GEINO-014 TRIAL by Balana, C, Sepulveda, J, Pineda, E, Vaz, M, Mesia, C, Fuster, J, Girones, R, Muñoz-Langa, J, Navarro, M, Alonso, M, Gil Gil, M, Herrero, A, Estival, A, Gallego, O, Peralta, S, Olier, C, Pérez-Segura, P, Covela, M, Martinez García, M, Domenech, M, Carrato, C, Sanz, C, Velarde, J, Berrocal, A, Luque, R, De las Peñas, R, Del Barco, S

“…Abstract BACKGROUND Standard treatment of glioblastoma (GBM) is focal radiation with concomitant and adjuvant temozolomide (TMZ) for 6 cycles. The GEINO-14-01…”
Get full text

High reduction of circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin) by Manso, L., Moreno, F., Delgado, J.I., Echarri, M.J., López, A., Izarzugaza, Y., Borrega, P., Martínez, N., Olier, C., Cortes-Funes, H.

Get full text

Significance of Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Nsclc Treated with Pemetrexed Based Chemotherapy by Mielgo, X., Velastegui Ordoñez, A., Martínez Cabañes, R., Rosero, A.C., Ruiz-Giménez, L., Cámara, J.C., Hernando, S., Hurtado, A., Olier, C.

Get full text

Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes: Onsite study (ONCOSUR 2012-02) by Sánchez, L.M. Manso, Antón, F. Moreno, Perón, Y. Izarzugaza, De Mingorance, J. Ilgado, Borrega, P., González, M.J. Echarri, Martínez, N., González, A. López, Olier, C., García, A. Ballesteros, Chacón, I., Ciruelos, E., García-Sáenz, J.A., Paz-Ares, L.

Get full text

Evaluation of Aromatase Inhibitor-Related Arthralgia in Early Breast Cancer Patients by Laorden, N. Romero, Olier, C., Mielgo, X., Falagán, S., Velástegui, A., Hernando, S., Cámara, J.C., Hurtado, A., Garcia-Donas, J., Jara, C.

Get full text

New treatments for renal carcinoma by Pérez-Gracia, J L, López-Picazo, J M, Olier, C, Alfaro, C, García-Foncillas, J, Melero, I, Gúrpide, A

“…Renal cell carcinoma presents several unique features, which distinguish it from other tumours. The increase in survival that has been described in patients…”
Get full text

Pilot study of the combination of capecitabine + oxaliplatin as adjuvant therapy for patients with stage III and high risk stage II colon cancer by Olier, C., Reyna, C., Aramendia, J. M., Rodriguez, J., Viudez, A., Chopitea, A., Garcia-Foncillas, J.

“…Abstract only…”
Get full text

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication by Schneeweiss, A., Peretz-Yablonski, T., Nowecki, Z., Merot, J.-L., Pena-Murillo, C., Bachelot, T., Coudert, B., Nowecki, Z., Wardley, A., Puglisi, F., Montemurro, F., Hu, X., Gaafar, R., Li, H., Aktas, B., Tienghi, A., Miles, D., Lux, M., Menjon Beltran, S., Turner, N., Tong, Z., Boer, K., Horvath, Z., Susnjar, S., Matos, E., Garcia Estevez, L., Cruz, M., Bourgeois, H., von Schumann, R., Morales-Vásques, F., Voitko, N., Hicks, J., Barrett-Lee, P., Wheatley, D., Gozy, M., Latini, L., Barnadas Molins, A., Bratos, R., McCarthy, N., Kee, D., Artignan, X., Azribi, F., Jaafar, H., Augereau, P., Müller, V., Evron, E., Cascinu, S., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Kukulska, M., Levitt, N., Panwar, U., Rigg, A., Fein, L., Malik, L., Singer, C., Stoeger, H., Cedeño, M., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Fried, G., Moscetti, L., Siddiqi, N., Arcediano Del Amo, A., McAdam, K., Dunn, G., Taylor, W., Hegg, R., Grosjean, J., Laplaige, P., Christensen, B., Zahm, D.-M., Inbar, M., Bonetti, A., van der Velden, A., van Warmerdam, L., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Joffe, J., Nobre, A., Jiang, J., Padrik, P., Dohollou, N., Prulhiere, K., Ober, A., Alabiso, O., van de Wouw, A.J., Saadein, A., Abdelhafiez, N., Abulkhair, O., Llorente Domenech, R., Gil Raga, M., Rodriguez Sanchez, C., Torrego Garcia, J., Vicente Rubio, E., Jones, A., Alonso, I.

“…The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as…”
Get full text

CEA response as a prognostic marker in non-small-cell lung carcinoma (NSCLC) patients treated with gefitinib or erlotinib by Ceballos, J., Lopez-Picazo, J., Reyna, C., Moreno Jimenez, M., Pérez-Gracia, J. L., Ponz Sarvise, M., Olier, C., Gil Bazo, I., Gurpide, A., Garcia-Foncillas, J.

“…Abstract only…”
Get full text

Evaluating response with endoscopic ultrasound (EUS) after preoperative chemoradiation (CHRT) in gastric cancer by Diaz-Gonzalez, J. A., Rodriguez, J., Olier, C., Arbea, L., Viudez, A., Aristu, J., Chopitea, A., Subtil, J. C., Martin- Algarra, S., Garcia-Foncillas, J.

“…Abstract only…”
Get full text

Hepatic arterial infusion (HAI) of oxaliplatin combined with docetaxel and capecitabine in patients with liver metastases from non-colorectal gastrointestinal tumours: A dose-finding study by Hernandez, A., Rodriguez, J., Viudez, A., Chopitea, A., Bandres, E., Zarate, R., Ponz-Sarvise, M., Olier, C., Reyna, C., Garcia-Foncillas, J.

“…Abstract only…”
Get full text